Overview

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection

Status:
RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
Phase III trial evaluating doravirine as an alternative to dolutegravir in treatment naïve people living with HIV-1 infection.
Phase:
PHASE3
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases
Collaborators:
European and Developing Countries Clinical Trials Partnership (EDCTP)
MSD France
Treatments:
dolutegravir
doravirine
Emtricitabine
Lamivudine
Tenofovir